Use of ketamine in refractory depression in an adolescent patient: Case report
DOI:
https://doi.org/10.20453/rnp.v88i1.5914Keywords:
depression, ketamine, adolescent psychiatry, antidepressive agents, refractory period, psychologicalAbstract
Refractory depression is defined as a depressive disorder that does not respond to psychotherapy and two periods of pharmacological management. During adolescence, depression may have different manifestations than in adults, with therapeutic interventions based on the same premise but with variations for each age group. The prevalence of refractory depression is showing a progressive increase, a reason for which the search for more effective management is fundamental. In the midst of the initiatives to address it, the use of ketamine has been proposed, and several authors have detailed different therapeutic doses, duration of treatment and adverse effects. We present the case of a patient with long-term depression, who had undergone multiple therapeutic interventions, without symptomatic control, and who is currently receiving a ketamine regimen with promising results.
Downloads
References
García G, Corral RM, Lupo C, Vilapriño M, Alessandria H, Kanevsky G, et al. Trastorno depresivo mayor y depresión resistente al tratamiento: un análisis epidemiológico en Argentina del estudio de depresión resistente al tratamiento en América Latina. Vertex Rev Arg Psiquiatr [Internet]. 2022; 33(155): 36-49. Disponible en: https://doi.org/10.53680/vertex.v33i155.134
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual research review: Defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry [Internet]. 2020; 61(3): 312-332. Disponible en: https://doi.org/10.1111/jcpp.13202
Rivera D, Susunaga PA, Pérez MA. Ketamine: state of the art. RFS Revista Facultad Salud [Internet]. 2013; 5(1): 83-93. Disponible en: https://doi.org/10.25054/rfs.v5i1.134
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry [Internet]. 1994; 51(3): 199-214. Disponible en: https://doi.org/10.1001/archpsyc.1994.03950030035004
Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology [Internet]. 2024; 49(1): 41-50. Disponible en: https://doi.org/10.1038/s41386-023-01629-w
Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science [Internet]. 2019; 364(6436): eaat8078. Disponible en: https://doi.org/10.1126/science.aat8078
Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science [Internet]. 2010; 329(5994): 959-964. Disponible en: https://doi.org/10.1126/science.1190287
Nuñez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J Affect Disord [Internet]. 2022; 302: 385-400. Disponible en: https://doi.org/10.1016/j.jad.2021.12.134
Borbély É, Simon M, Fuchs E, Wiborg O, Czéh B, Helyes Z. Novel drug developmental strategies for treatment-resistant depression. Br J Pharmacol [Internet]. 2022; 179(6): 1146-1186. Disponible en: https://doi.org/10.1111/bph.15753
Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry [Internet]. 2021; 82(2): 20m13699. Disponible en: https://doi.org/10.4088/JCP.20m13699
Loo C, Glozier N, Barton D, Baune BT, Mills NT, Fitzgerald P, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry [Internet]. 2023; 223(6): 533-541. Disponible en: https://doi.org/10.1192/bjp.2023.79
Phillips JL, Norris S, Talbot J, Hatchard T, Ortiz A, Birmingham M, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology [Internet]. 2019; 45(4): 606-612. Disponible en: https://doi.org/10.1038/s41386-019-0570-x
Christodoulakis ΤΕ. [Ketamine infusion therapy in treatment-resistant depression]. Psychiatriki [Internet]. 2021; 32(suppl 1): 64-69. Disponible en: https://doi.org/10.22365/jpsych.2021.051 Griego
Zakhour S, Nardi AE, Levitan M, Appolinario JC. Cognitive-behavioral therapy for treatment-resistant depression in adults and adolescents: a systematic review. Trends Psychiatry Psychother [Internet]. 2020; 42(1): 92-101. Disponible en: https://doi.org/10.1590/2237-6089-2019-0033
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Juan David Rios Restrepo, Elvia Elena Pardo Cely, Omar Luis Perez Caldera, Lorena Gómez Agudelo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
RNP is distributed under a 